Repository logo

Dynamics of measles immunity from birth and following vaccination.

Accepted version

Change log


Wang, Qianli 
Zhao, Sihong 


Measles remains a major threat to human health despite widespread vaccination. While we know that maternal antibodies can impair vaccine-induced immunity, the relative contributions of pre-existing immunity levels, maternal and infant characteristics on vaccine responses remain unclear, hampering evidence-based vaccination policy development. Here we combine serological data from 1,505 individuals (aged 0-12 years) in a mother-infant cohort and in a child cohort with empirical models to reconstruct antibody trajectories from birth. We show that while highly heterogeneous across a population, measles antibody evolution is strongly predictive from birth at the individual level, including following vaccination. Further, we find that caesarean section births were linked with 2.56 (95% confidence interval: 1.06-6.37) increased odds of primary vaccine failure, highlighting the long-term immunological consequences of birth route. Finally, we use our new understanding of antibody evolution to critically assess the population-level consequences of different vaccination schedules, the results of which will allow country-level evaluations of vaccine policy.



3107 Microbiology, 31 Biological Sciences, Immunization, Rare Diseases, Clinical Research, Prevention, Infectious Diseases, Biotechnology, Vaccine Related, Biodefense, Pediatric, Emerging Infectious Diseases, 3.4 Vaccines, 3 Prevention of disease and conditions, and promotion of well-being, Generic health relevance, 3 Good Health and Well Being

Journal Title

Nat Microbiol

Conference Name

Journal ISSN


Volume Title


Springer Science and Business Media LLC
Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd.